Evaluating the effectiveness and safety of a remote electrical neuromodulation wearable device in treating chronic and episodic migraine: a retrospective, observational real-world evidence from India.
{"title":"Evaluating the effectiveness and safety of a remote electrical neuromodulation wearable device in treating chronic and episodic migraine: a retrospective, observational real-world evidence from India.","authors":"Sujeet Narayan Charugulla, Mayank Ravindra Dhore, Alit Stark-Inbar, Bhavesh Prabhudas Kotak, Sukhpreet Singh","doi":"10.1080/17434440.2025.2566742","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The remote electrical neuromodulation (REN) wearable device offers a noninvasive, non-pharmacological option for migraine management, but its role in Indian healthcare remains unexplored.</p><p><strong>Research design and methods: </strong>This retrospective, observational, real-world analysis included patients prescribed REN (Nerivio®) by neurologists across India. Deidentified data were collected via the Portea Medical patient support program, with a three-month follow-up. The primary outcome assessed the effectiveness and safety of the device. Secondary outcomes included changes in headache frequency and medication regimes.</p><p><strong>Results: </strong>The study population included 1033 patients (mean [SD] age: 38.8 [13] years; 74.8% female; 84.6% with chronic migraine). At two hours post-treatment with REN, 57.3% reported pain relief, 29.4% achieved pain freedom, 47.1% experienced relief from functional disability, and 26.1% reported complete freedom from functional disability. At three months, 70.3% found REN effective. The mean visual analog scale score for pain severity decreased by 2.3 units (<i>p</i> < 0.001). No adverse events occurred in 38.7% of patients. REN usage significantly reduced monthly headache days, frequency of oral medication use, and medicine dosage.</p><p><strong>Conclusion: </strong>REN is an effective, safe, and well-tolerated non-pharmacological option for migraine management in India. However, long-term studies are necessary to extend these findings across diverse populations.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov (CTRI/2024/11/076750).</p>","PeriodicalId":94006,"journal":{"name":"Expert review of medical devices","volume":" ","pages":"1-7"},"PeriodicalIF":2.7000,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert review of medical devices","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17434440.2025.2566742","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The remote electrical neuromodulation (REN) wearable device offers a noninvasive, non-pharmacological option for migraine management, but its role in Indian healthcare remains unexplored.
Research design and methods: This retrospective, observational, real-world analysis included patients prescribed REN (Nerivio®) by neurologists across India. Deidentified data were collected via the Portea Medical patient support program, with a three-month follow-up. The primary outcome assessed the effectiveness and safety of the device. Secondary outcomes included changes in headache frequency and medication regimes.
Results: The study population included 1033 patients (mean [SD] age: 38.8 [13] years; 74.8% female; 84.6% with chronic migraine). At two hours post-treatment with REN, 57.3% reported pain relief, 29.4% achieved pain freedom, 47.1% experienced relief from functional disability, and 26.1% reported complete freedom from functional disability. At three months, 70.3% found REN effective. The mean visual analog scale score for pain severity decreased by 2.3 units (p < 0.001). No adverse events occurred in 38.7% of patients. REN usage significantly reduced monthly headache days, frequency of oral medication use, and medicine dosage.
Conclusion: REN is an effective, safe, and well-tolerated non-pharmacological option for migraine management in India. However, long-term studies are necessary to extend these findings across diverse populations.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
